

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
11 August 2005 (11.08.2005)

PCT

(10) International Publication Number
WO 2005/073216 A3

(51) International Patent Classification⁷: **C07K 5/02**, (74) Agent: AWAPATENT AB; P.O. Box 45086, S-104 30 C07D 401/12, 409/14, 405/14, 413/14, 417/14, 207/16, Stockholm (SE).
A61K 31/47, A61P 31/12, C07D 487/04

(21) International Application Number:
PCT/SE2005/000096

(22) International Filing Date: 28 January 2005 (28.01.2005)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:
0400199-6 30 January 2004 (30.01.2004) SE
0401288-6 19 May 2004 (19.05.2004) SE
0402562-3 22 October 2004 (22.10.2004) SE

(71) Applicant (for all designated States except US): **MEDIVIR AB** [SE/SE]; Lunastigen 7, S-141 44 Huddinge (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ROSENQUIST, Åsa** [SE/SE]; c/o Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE). **THORSTENSSON, Fredrik** [SE/SE]; c/o IFM Faculty, University of Linköping, S-581 83 Linköping (SE). **JOHANSSON, Per-Ola** [SE/SE]; c/o IFM Faculty, University of Linköping, S-581 83 Linköping (SE). **KVARNSTRÖM, Ingemar** [SE/SE]; c/o IFM Faculty, University of Linköping, S-581 83 Linköping (SE). **AYESA, Susana** [ES/SE]; c/o Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE). **CLASSON, Björn** [SE/SE]; c/o Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE). **RAKOS, Lazlo** [SE/SE]; c/o Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE). **SAMUELSSON, Bertil** [SE/SE]; c/o Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE).

(54) Title: HCV NS-3 SERINE PROTEASE INHIBITORS



(57) Abstract: Compounds of the formula (F) where the variables are as defined in the specification inhibit the NS3 protease of flavivirus such as hepatitis C virus (HCV). The compounds comprise a novel linkage between a heterocyclic P2 unit and those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.

WO 2005/073216 A3